Download Files:
Ralaniten triacetate
$500 – $4,600
Products Details
Product Description
– Ralaniten triacetate (EPI-506), the pro-agent of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7[1][2].
Web ID
– HY-123875A
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C27H33ClO8
References
– [1]Obst JK, et al. Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies. ACS Pharmacol Transl Sci. 2019;2(6):453-467. Published 2019 Sep 26.|[2]Chi, Kim Nguyen et al. Efficacy, safety, tolerability, and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after enzalutamide and/or abiraterone. Journal of Clinical Oncology 35 (2017): 5032-5032.
CAS Number
– 1637573-04-6
Molecular Weight
– 521.00
Compound Purity
– 98.79
SMILES
– CC(C(C=C1)=CC=C1OC[C@@H](CCl)OC(C)=O)(C(C=C2)=CC=C2OC[C@H](OC(C)=O)COC(C)=O)C
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Androgen Receptor
Pathway
– Vitamin D Related/Nuclear Receptor
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
